Impact of prostate-specific antigen screening on the natural history of prostate cancer

Urology

Volumn 46, Issue 6, 1995, Pages 757-768

  Rosen, Mark A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; EARLY DIAGNOSIS; HUMAN; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

ADULT; AGED; HUMAN; MALE; MASS SCREENING; MIDDLE AGE; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0028852060     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80339-2     Document Type: Article

References (95)

1. Cancer statistics, 1995
2. Epidemiologic aspects of latent and clinically manifest carcinoma of the prostate
3. Watchful waiting for early stage prostate cancer
4. Trends in patterns of care for prostatic cancer, 1974–1983: results of surveys by the American College of Surgeons
5. Prognostic significance of lymph nodal metastases in prostate cancer
6. High 10-year survival rate in patients with early, untreated prostatic cancer
7. Male genital cancers
8. The nature of prostate cancer detected through prostate specific antigen based screening
9. Early detection of prostate cancer
10. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening [see comments]
11. Patient age as a prognostic factor in prostate cancer.
12. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
13. The risk of dying of prostate cancer in patients with clinically localized disease
14. Bilateral adrenalectomy in prostatic cancer. Clinical features and urinary excretion of 17ketosteroids and estrogen
15. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU group and EORTC data center
16. Treatment of newly diagnosed metastatic prostate cancer with chemotherapy in combination with hormones alone
17. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
18. A critical assessment of the role of chemotherapy for endocrine-resistant prostatic carcinoma
19. Radiation therapy for cancer of the prostate
20. Statistical and epidemiological data on urologic cancer
21. Nodal involvement as a prognostic indicator in patients with prostatic carcinoma
22. The treatment of stage C prostatic cancer with special reference to combined surgical and radiation treatment
23. Prostatic adenocarcinoma: relationship of grade and local extent to the pattern of metastases
24. Prognosis of patients with stage D1 prostatic adenocarcinoma
25. Prognostic factors in men with stage D1 prostate cancer: identification of patients less likely to have prolonged survival after radical prostatectomy [see comments]
26. Radical excision of adenocarcinoma of prostate with pelvic lymph node involvement: surgical gesture or curative procedure
27. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact of time to progression
28. The prognostic role of lymphadenectomy in adenocarcinoma of the prostate
29. Extended field radiation therapy versus delayed hormonal therapy in node positive prostatic adenocarcinoma
30. The value of testosterone deprivation in stage D1 carcinoma of the prostate
31. Management of stage D1 adenocarcinoma of the prostate: the Johns Hopkins experience 1974 to 1987
32. Impact of external beam irradiation on local symptoms and survival free of disease in patients with pelvic lymph node metastases from adenocarcinoma of the prostate
33. Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome
34. Adjuvant therapy for localized prostate cancer
35. Radical prostatectomy for stage D1 prostate cancer
36. Stage D1 prostate cancer. A nonrandomized comparison of conservative treatment options versus radical prostatectomy
37. The challenge of treating node positive prostate cancer: an approach to resolving the questions
38. Is long term survival possible with external beam irradiation for stage D1 adenocarcinoma of the prostate?
39. Result of treatment of patients with stage D1 prostatic carcinoma
40. Adjuvant radiation, chemotherapy and androgen deprivation therapy for pathologic stage D1 adenocarcinoma of the prostate
41. Radical prostatectomy for carcinoma of the prostate: 1951–1976. A review of 329 patients
42. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer
43. Radical prostatectomy: palliation for stage C carcinoma of the prostate
44. The frequency and morbidity of local tumor recurrence after definitive radiotherapy for stage C prostate cancer
45. Current status of screening for lung cancer
46. Screening for prostate cancer
47. Pelvic lymph node dissection
48. Pathological features and prognosis of prostate cancer detectable with current diagnostic tests
49. Impact of routine screening for adenocarcinoma of the prostate on stage distribution
50. Adenocarcinoma of the prostate: results of routine urological screening
51. Assessment of screening for prostate cancer using the digital rectal exam
52. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men
53. Serum prostate specific antigen as a pre-screening test for prostate cancer
54. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination
55. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen
56. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer
57. Progress and problems in screening for carcinoma of the prostate
58. Sensitivity and specificity of first screen mammography in 15 NBSS centres
59. Positive predictive value of screening mammography by age and family history of breast cancer [see comments]
60. Screening for breast cancer in Nijmegen. Report of 6 screening rounds, 1975–1986
61. A mammographic screening pilot project in Victoria 1988-1990. The Essendon Breast X-ray Program Collaborative Group.
62. Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project
63. Screening for prostate cancer by digital rectal examination and PSA. Results of prostate cancer awareness week, 1989–1992
64. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome
65. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy
66. Prognostic significance of positive surgical margins in radical prostatectomy specimens
67. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease
68. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume
69. Clinical observations on the doubling time of prostate cancer
70. Natural history of changes in prostate specific antigen in early stage prostate cancer
71. Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations
72. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies
73. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stage T1A and T1B) and on needle biopsy (stage T1C)
74. Deferred treatment in clinically localised prostatic carcinoma
75. Natural history of localised prostatic cancer managed by conservative therapy alone
76. Expectant management of localized prostatic cancer
77. Results of conservative management of clinically localized prostate cancer
78. The evaluation and treatment of men with asymptomatic prostate nodules in primary care: a decision analysis
79. Screening for prostate cancer. A decision analytic view
80. A decision analysis of alternative treatment strategies for clinically localized prostate cancer
81. A Markov model of the natural history of prostate cancer
82. A critique of the decision analysis for clinically localized prostate cancer
83. Impact and cost-effectiveness of smoking interventions
84. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
85. The histology and prognosis of prostatic cancer
86. Gleason grading of prostate cancer: a predictor of survival
87. Radical prostatectomy for clinical stage T1-2NOMO prostatic carcinoma: long-term results
88. Radical surgery for prostate cancer
89. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer?
90. Radical prostatectomy for high grade disease: a reevaluation 1994
91. How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization? A dynamic population model approach.
92. Modelling the analysis of breast cancer screening programmes: sensitivity, lead time and predictive value in the Florence District Programme (1975–1986)
93. Cervical cancer screening programs: the Walton report
94. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute.
95. The Prostate Cancer Intervention Versus Observation Trial: a randomization trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer